1
|
Wéber A, Morgan E, Vignat J, Laversanne M, Pizzato M, Rumgay H, Singh D, Nagy P, Kenessey I, Soerjomataram I, Bray F. Lung cancer mortality in the wake of the changing smoking epidemic: a descriptive study of the global burden in 2020 and 2040. BMJ Open 2023; 13:e065303. [PMID: 37164477 PMCID: PMC10174019 DOI: 10.1136/bmjopen-2022-065303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/07/2022] [Accepted: 04/04/2023] [Indexed: 05/12/2023] Open
Abstract
OBJECTIVES Lung cancer (LC) is the leading cause of cancer death in 2020, responsible for almost one in five (18.0%) deaths. This paper provides an overview of the descriptive epidemiology of LC based on national mortality estimates for 2020 from the International Agency for Research on Cancer (IARC), and in the context of recent tobacco control policies. DESIGN AND SETTING For this descriptive study, age-standardised mortality rates per 100 000 person-years of LC for 185 countries by sex were obtained from the GLOBOCAN 2020 database and stratified by Human Development Index (HDI). LC deaths were projected to 2040 based on demographic changes alongside scenarios of annually increasing, stable or decreasing rates from the baseline year of 2020. RESULTS LC mortality rates exhibited marked variations by geography and sex. Low HDI countries, many of them within sub-Saharan Africa, tend to have low levels of mortality and an upward trend in LC deaths is predicted for both sexes until 2040 according to demographic projections, irrespective of trends in rates. In very high HDI countries, including Europe, Northern America and Australia/New Zealand, there are broadly decreasing trends in men whereas in women, rates are still increasing or reaching a plateau. CONCLUSION The current and future burden of LC in a country or region largely depends on the present trajectory of the smoking epidemic in its constituent populations, with distinct gender differences in smoking patterns, both in transitioning and transitioned countries. Further elevations in LC mortality are expected worldwide, raising important social and political questions, especially in low-income and middle-income countries.
Collapse
Affiliation(s)
- András Wéber
- Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France
- Hungarian National Cancer Registry and National Tumor Biology Laboratory, National Institute of Oncology, Budapest, Hungary
| | - Eileen Morgan
- Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France
| | - Jerome Vignat
- Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France
| | - Mathieu Laversanne
- Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France
| | - Margherita Pizzato
- Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France
- Department of Clinical Sciences and Community Health, University of Milan, Milano, Italy
| | - Harriet Rumgay
- Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France
| | - Deependra Singh
- Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France
| | - Péter Nagy
- Department of Molecular Immunology and Toxicology and the National Tumor Biology Laboratory, National Institute of Oncology, Budapest, Hungary
- Department of Anatomy and Histology, Laboratory of Redox Biology, University of Veterinary Medicine, Budapest, Hungary
- Chemistry Institute, University of Debrecen, Debrecen, Hungary
| | - István Kenessey
- Hungarian National Cancer Registry and National Tumor Biology Laboratory, National Institute of Oncology, Budapest, Hungary
- Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, Budapest, Hungary
| | | | - Freddie Bray
- Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France
| |
Collapse
|
2
|
Luo G, Zhang Y, Etxeberria J, Arnold M, Cai X, Hao Y, Zou H. Projections of Lung Cancer Incidence by 2035 in 40 Countries Worldwide: Population-Based Study. JMIR Public Health Surveill 2023; 9:e43651. [PMID: 36800235 PMCID: PMC9984998 DOI: 10.2196/43651] [Citation(s) in RCA: 30] [Impact Index Per Article: 30.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2022] [Revised: 12/16/2022] [Accepted: 01/11/2023] [Indexed: 02/18/2023] Open
Abstract
BACKGROUND The global burden of lung cancer (LC) is increasing. Quantitative projections of the future LC burden in different world regions could help optimize the allocation of resources and provide a benchmark for evaluating LC prevention and control interventions. OBJECTIVE We aimed to predict the future incidence of LC in 40 countries by 2035, with an emphasis on country- and sex-specific disparities. METHODS Data on LC incidence from 1978 to 2012 were extracted from 126 cancer registries of 40 countries in Cancer Incidence in Five Continents Volumes V-XI and used for the projection. Age-standardized incidence rates (ASRs) per 100,000 person-years and the number of incident cases were predicted through 2035, using the NORDPRED age-period-cohort model. RESULTS Global ASRs of the 40 studied countries were predicted to decrease by 23% (8.2/35.8) among males, from 35.8 per 100,000 person-years in 2010 to 27.6 in 2035, and increase by 2% (0.3/16.8) among females, from 16.8 in 2010 to 17.1 in 2035. The ASRs of LC among females are projected to continue increasing dramatically in most countries by 2035, with peaks after the 2020s in most European, Eastern Asian, and Oceanian countries, whereas the ASRs among males will continue to decline in almost all countries. The ASRs among females are predicted to almost reach those among males in Ireland, Norway, the United Kingdom, the Netherlands, Canada, the United States, and New Zealand in 2025 and in Slovenia in 2035 and even surpass those among males in Denmark in 2020 and in Brazil and Colombia in 2025. In 2035, the highest ASRs are projected to occur among males in Belarus (49.3) and among females in Denmark (36.8). The number of new cases in 40 countries is predicted to increase by 65.32% (858,000/1,314,000), from 1.31 million in 2010 to 2.17 million in 2035. China will have the largest number of new cases. CONCLUSIONS LC incidence is expected to continue to increase through 2035 in most countries, making LC a major public health challenge worldwide. The ongoing transition in the epidemiology of LC highlights the need for resource redistribution and improved LC control measures to reduce future LC burden worldwide.
Collapse
Affiliation(s)
- Ganfeng Luo
- School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, China
| | - Yanting Zhang
- Department of Medical Statistics, School of Public Health, Sun Yat-sen University, Guangzhou, China
- Department of Epidemiology and Health Statistics, School of Public Health, Guangdong Medical University, Dongguan, China
| | - Jaione Etxeberria
- Department of Statistics, Computer Science and Mathematics, Public University of Navarre, Navarre, Spain
- Institute for Advanced Materials and Mathematics (INAMAT2), Public University of Navarre, Navarre, Spain
| | - Melina Arnold
- Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France
| | - Xiuyu Cai
- Department of VIP Inpatient, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
| | - Yuantao Hao
- Department of Medical Statistics, School of Public Health, Sun Yat-sen University, Guangzhou, China
- Peking University Center for Public Health and Epidemic Preparedness & Response, Peking University, Beijing, China
| | - Huachun Zou
- School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, China
- Kirby Institute, University of New South Wales, Sydney, Australia
| |
Collapse
|
3
|
Clustering Trend Changes of Lung Cancer Incidence in Europe via the Growth Mixture Model during 1990-2016. JOURNAL OF ENVIRONMENTAL AND PUBLIC HEALTH 2021; 2021:8854446. [PMID: 33897783 PMCID: PMC8052171 DOI: 10.1155/2021/8854446] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/19/2020] [Revised: 03/21/2021] [Accepted: 03/30/2021] [Indexed: 11/17/2022]
Abstract
Background Lung cancer accounts for half of all deaths from cancer in Europe and has the highest incidence in Southern Europe. The current study aimed to cluster trend changes of lung cancer incidence in Europe via the growth mixture model. Methods The dataset included incidence rates of female and male lung cancer per 100,000 for 42 European countries during 1990–2016 compiled from the Gapminder database. The growth mixture model was implemented to recognize different longitudinal patterns and estimate the linear trend of each pattern in Mplus 7.4 software. Results The observed overall trend of incidence for female and male lung cancer was raising and falling, respectively, and Iceland was the only country with higher incidence of female versus male lung cancer in 2016. The growth mixture model suggests 3 main patterns for the trend of lung cancer incidence both for males and females. In male lung cancer, a sharp decreasing pattern was detected for 6 countries including Belarus, Estonia, Russia, Slovenia, Ukraine, and the United Kingdom; also, a moderately decreasing pattern was observed among the other countries. In female lung cancer, a moderate increasing trend was observed for 8 countries including the United Kingdom, Denmark, Hungary, Iceland, Ireland, Montenegro, Netherlands, and Norway; the other patterns were categorized into two clusters with slow increasing trends. Conclusion Given the raising patterns in the incidence of lung cancer among European females, especially in the United Kingdom, Denmark, Hungary, Iceland, Ireland, Montenegro, Netherlands, and Norway, urgent effective measures are recommended to be taken.
Collapse
|
4
|
Liu G, Pei F, Yang F, Li L, Amin AD, Liu S, Buchan JR, Cho WC. Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer. Int J Mol Sci 2017; 18:E367. [PMID: 28208579 PMCID: PMC5343902 DOI: 10.3390/ijms18020367] [Citation(s) in RCA: 242] [Impact Index Per Article: 34.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2016] [Revised: 01/22/2017] [Accepted: 02/03/2017] [Indexed: 02/07/2023] Open
Abstract
Non-small-cell lung cancer (NSCLC) constitutes 85% of all lung cancers, and is the leading cause of cancer-related death worldwide. The poor prognosis and resistance to both radiation and chemotherapy warrant further investigation into the molecular mechanisms of NSCLC and the development of new, more efficacious therapeutics. The processes of autophagy and apoptosis, which induce degradation of proteins and organelles or cell death upon cellular stress, are crucial in the pathophysiology of NSCLC. The close interplay between autophagy and apoptosis through shared signaling pathways complicates our understanding of how NSCLC pathophysiology is regulated. The apoptotic effect of autophagy is controversial as both inhibitory and stimulatory effects have been reported in NSCLC. In addition, crosstalk of proteins regulating both autophagy and apoptosis exists. Here, we review the recent advances of the relationship between autophagy and apoptosis in NSCLC, aiming to provide few insights into the discovery of novel pathogenic factors and the development of new cancer therapeutics.
Collapse
Affiliation(s)
- Guangbo Liu
- Department of Molecular and Cellular Biology, University of Arizona, Tucson, AZ 85721, USA.
| | - Fen Pei
- Department of Molecular and Cellular Biology, University of Arizona, Tucson, AZ 85721, USA.
| | - Fengqing Yang
- Department of Obstetrics and Gynecology, Dong'e No. 4 People's Hospital, Liaocheng 252200, China.
| | - Lingxiao Li
- Department of Medicine, Division of Hematology-Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
| | - Amit Dipak Amin
- Department of Medicine, Division of Hematology-Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
| | - Songnian Liu
- Department of Chemical and Life Science Engineering, Virginia Commonwealth University, Richmond, VA 23284, USA.
| | - J Ross Buchan
- Department of Molecular and Cellular Biology, University of Arizona, Tucson, AZ 85721, USA.
| | - William C Cho
- Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong, China.
| |
Collapse
|
5
|
Bryła M, Pikala M, Maniecka-Bryła I. Years of Life Lost due to Premature Mortality in a Province with the Shortest Life Expectancy in Poland. Cent Eur J Public Health 2016; 24:156-62. [PMID: 27434249 DOI: 10.21101/cejph.a4289] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2015] [Accepted: 06/17/2015] [Indexed: 11/15/2022]
Abstract
AIM The aim of the study was to evaluate years of life lost for citizens of the Lodz Province, which is characterized by the lowest life expectancy in Poland, and to identify current trends in this area according to the most common causes of death. METHODS The study material included a database containing information gathered from 470,000 death certificates of Lodz Province inhabitants, who died between 1999 and 2011. In order to calculate years of life lost, the authors applied the SEYLLp (Standard Expected Years of Life Lost per living person) and SEYLLd (per death) indices. The analysis of time trends was carried out with the application of joinpoint models. RESULTS The SEYLLp measure was 2,300 years per 10,000 males and 1,500 years per 10,000 females in 2011. Cardiovascular diseases contributed to the highest number of years of life lost (SEYLLp=682 years per 10,000 males and 559 years per 10,000 females). Next were malignant neoplasms (SEYLLp=505 years per 10,000 males and 437 years per 10,000 females), external causes of death (SEYLLp=361 years per 10,000 males and 83 years per 10,000 females). The number of years of life lost due to acute myocardial infarction decreased most rapidly, the Annual Percent Change (APC) was -10.1% in males and -3.7% in females. However, heart failure contributed to the highest increase in the number of years of life lost (APC=10.8% in males and 10.9% in females). CONCLUSIONS A further decrease in the mortality rate due to cardiovascular diseases might contribute to the highest reduction of years of life lost. The most effective preventive activities are those aimed at reducing productive years of life lost due to a particular cause of death, i.e. road traffic accidents, suicides, cirrhosis of the liver, alcoholic liver disease, and malignant neoplasms of the trachea, bronchi and lungs.
Collapse
Affiliation(s)
- Marek Bryła
- Social Medicine Department, Medical University of Lodz, Lodz, Poland
| | - Małgorzata Pikala
- Epidemiology and Biostatistics Department, Medical University of Lodz, Lodz, Poland
| | - Irena Maniecka-Bryła
- Epidemiology and Biostatistics Department, Medical University of Lodz, Lodz, Poland
| |
Collapse
|
6
|
A Relational Database of WHO Mortality Data Prepared to Facilitate Global Mortality Research. OPEN HEALTH DATA 2015. [DOI: 10.5334/ohd.ao] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
7
|
Mocci E, Guillen-Ponce C, Earl J, Marquez M, Solera J, Salazar-López MT, Calcedo-Arnáiz C, Vázquez-Sequeiros E, Montans J, Muñoz-Beltrán M, Vicente-Bártulos A, González-Gordaliza C, Sanjuanbenito A, Guerrero C, Mendía E, Lisa E, Lobo E, Martínez JC, Real FX, Malats N, Carrato A. PanGen-Fam: Spanish registry of hereditary pancreatic cancer. Eur J Cancer 2015. [PMID: 26212471 DOI: 10.1016/j.ejca.2015.07.004] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
PURPOSE To describe the organisation of the registry and the preliminary results in terms of characteristics of high-risk pancreatic ductal adenocarcinoma (PDAC) families recruited to date and findings of the screening programme. To compare early onset sporadic cases (⩽50 years), sporadic cases (>50 years) and cases with family history of cancer, for PDAC possible risk factors. METHODS/PATIENTS Families with hereditary cancer syndromes predisposing to PDAC were recruited from two main sources: Spanish hospitals participating in PanGenEU, a pan-European multicentre case-control study, and their genetic counseling unit. Individuals at high-risk of PDAC were enrolled into a screening programme, consisting of Endoscopic ultrasound, computerised tomography, magnetic resonance imaging. Genetic testing of candidate genes was offered according to each patient's risk. RESULTS Among 577 consecutive PDAC cases, recruited via PanGenEU, 36 (6%) had ⩾2 first-degree relative with PDAC: Familial pancreatic cancer (FPC). So far PanGen-Fam has recruited 42 high-risk PDAC families; 25 (60%) had FPC. Five index cases with cancer were positive for BRCA2 and one for BRCA1 germline mutations. In the second year of prospective PDAC screening, one neuroendocrine tumour and a high-grade dysplasia lesion suspicious of carcinoma were diagnosed among 41 high-risk individuals. Furthermore EUS detected chronic-pancreatitis-like parenchymal changes in 15 patients. CONCLUDING STATEMENT The identification and recruitment of PDAC high-risk families into the PanGen-Fam registry provides an opportunity to detect early onset cancer and precursor pancreatic cancer lesions at a potentially curative stage and to increase the knowledge of the natural history of the disease.
Collapse
Affiliation(s)
- E Mocci
- Medical Oncology Department, Ramon y Cajal University Hospital, IRYCIS, Madrid, Spain
| | - C Guillen-Ponce
- Medical Oncology Department, Ramon y Cajal University Hospital, IRYCIS, Madrid, Spain
| | - J Earl
- Medical Oncology Department, Ramon y Cajal University Hospital, IRYCIS, Madrid, Spain
| | - M Marquez
- Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - J Solera
- Molecular Oncogenetics Unit, Institute of Medical and Molecular Genetics, La Paz Hospital, Madrid, Spain
| | - M-T Salazar-López
- Medical Oncology Department, Ramon y Cajal University Hospital, IRYCIS, Madrid, Spain
| | - C Calcedo-Arnáiz
- Medical Oncology Department, Ramon y Cajal University Hospital, IRYCIS, Madrid, Spain
| | - E Vázquez-Sequeiros
- Digestive Department, Ramon y Cajal University Hospital, IRYCIS, Madrid, Spain
| | - J Montans
- Pathology Department, Ramon y Cajal University Hospital, IRYCIS, Madrid, Spain
| | - M Muñoz-Beltrán
- Radiology Department, Ramon y Cajal University Hospital, IRYCIS, Madrid, Spain
| | - A Vicente-Bártulos
- Radiology Department, Ramon y Cajal University Hospital, IRYCIS, Madrid, Spain
| | | | - A Sanjuanbenito
- Surgery Department, Ramon y Cajal University Hospital, IRYCIS, Madrid, Spain
| | - C Guerrero
- Medical Oncology Department, Ramon y Cajal University Hospital, IRYCIS, Madrid, Spain
| | - E Mendía
- Surgery Department, Ramon y Cajal University Hospital, IRYCIS, Madrid, Spain
| | - E Lisa
- Surgery Department, Ramon y Cajal University Hospital, IRYCIS, Madrid, Spain
| | - E Lobo
- Surgery Department, Ramon y Cajal University Hospital, IRYCIS, Madrid, Spain
| | - J C Martínez
- Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - F X Real
- Epithelial Carcinogenesis Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; Department de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain
| | - N Malats
- Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - A Carrato
- Medical Oncology Department, Ramon y Cajal University Hospital, IRYCIS, Madrid, Spain
| |
Collapse
|
8
|
Maniecka-Bryła I, Bryła M, Bryła P, Pikala M. The burden of premature mortality in Poland analysed with the use of standard expected years of life lost. BMC Public Health 2015; 15:101. [PMID: 25884915 PMCID: PMC4328237 DOI: 10.1186/s12889-015-1487-x] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2014] [Accepted: 01/28/2015] [Indexed: 11/20/2022] Open
Abstract
Background Despite positive changes in the health of the population of Poland, compared to the EU average, the average life expectancy in 2011 was 5 years shorter for males and 2.2 years shorter for females. The immediate cause is the great number of premature deaths, which results in years of life lost in the population. The aim of the study was to identify the major causes of years of life lost in Poland. Methods The analysis was based on a database of the Central Statistical Office of Poland, containing information gathered from 375,501 death certificates of inhabitants of Poland who died in 2011. The SEYLLp (Standard Expected Years of Life Lost per living person) and the SEYLLd (SEYLL per death) measures were calculated to determine years of life lost. Results In 2011, the total number of years of life lost by in Polish residents due to premature mortality was 2,249,213 (1,415,672 for males and 833,541 for females). The greatest number of years of life lost in males were due to ischemic heart disease (7.8 per 1,000), lung cancer (6.0), suicides (6.6), cerebrovascular disease (4.6) and road traffic accidents (5.4). In females, the factors contributing to the greatest number of deaths were cerebrovascular disease (3.8 per 1,000), ischemic heart disease (3.7), heart failure (2.7), lung cancer (2.5) and breast cancer (2.3). Regarding the individual scores per person in both males and females, the greatest death factors were road traffic accidents (20.2 years in males and 17.1 in females), suicides (17.4 years in males and 15.4 in females) and liver cirrhosis (12.1 years in males and 11.3 in females). Conclusions It would be most beneficial to further reduce the number of deaths due to cardiovascular diseases, because they contribute to the greatest number of years of life lost. Moreover, from the economic point of view, the most effective preventative activities are those which target causes which result in a large number of years of life lost at productive age for each death due to a particular reason, i.e. road traffic accidents, suicides and liver cirrhosis.
Collapse
Affiliation(s)
- Irena Maniecka-Bryła
- Department of Epidemiology and Biostatistics, Chair of Social and Preventive Medicine, Medical University of Lodz, Żeligowskiego 7/9, Lodz, Poland. .,Department of Social Medicine, Chair of Social and Preventive Medicine, Medical University of Lodz, Żeligowskiego 7/9, Lodz, Poland.
| | - Marek Bryła
- Department of Social Medicine, Chair of Social and Preventive Medicine, Medical University of Lodz, Żeligowskiego 7/9, Lodz, Poland.
| | - Paweł Bryła
- Department of International Marketing and Retailing, University of Lodz, Narutowicza 59a, Lodz, Poland.
| | - Małgorzata Pikala
- Department of Epidemiology and Biostatistics, Chair of Social and Preventive Medicine, Medical University of Lodz, Żeligowskiego 7/9, Lodz, Poland.
| |
Collapse
|
9
|
Pikala M, Maniecka-Bryla I. Years of life lost due to malignant neoplasms characterized by the highest mortality rate. Arch Med Sci 2014; 10:999-1006. [PMID: 25395953 PMCID: PMC4223125 DOI: 10.5114/aoms.2013.36237] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/13/2012] [Revised: 04/05/2013] [Accepted: 05/15/2013] [Indexed: 11/17/2022] Open
Abstract
INTRODUCTION The analysis of premature deaths measured with years of life lost between the studied and referential populations helps to emphasize the social and economic aspect of a loss caused by deaths due to malignant neoplasms. The aim of the study was to analyze years of life lost by inhabitants of the Lodz province due to malignant neoplasms. MATERIAL AND METHODS The study material included a database which contained information gathered from 313,144 death certificates (including 66,899 people who died of malignant neoplasms) of inhabitants of the Lodz province who died between 1999 and 2008. The SEYLLp (Standard Expected Years of Life Lost per living person) method was used to determine years of life lost. Jointpoint models were used to analyze time trends. RESULTS In males the diseases which mostly contributed to death were tracheal, bronchial and lung malignant neoplasms (SEYLLp = 170.7) and cancer of the large intestine, rectum and anus (SEYLLp = 47.5). In females the principal diseases were tracheal, bronchial and lung malignant neoplasms (SEYLLp = 61.6), breast cancer (SEYLLp = 60.4) and cancer of the large intestine, rectum and anus (SEYLLp = 42.3). The years of life lost were growing in the period under study. CONCLUSIONS The number of years lost due to malignant neoplasms in the Lodz province between 1999 and 2008 was growing. The main reasons for deaths in females were tracheal, bronchial and lung malignant neoplasms as well as breast cancer and in males - cancer of the large intestine, rectum and anus as well as prostate cancer.
Collapse
Affiliation(s)
- Malgorzata Pikala
- Department of Epidemiology and Biostatics, Medical University of Lodz, Poland
| | | |
Collapse
|
10
|
Torre LA, Siegel RL, Ward EM, Jemal A. International variation in lung cancer mortality rates and trends among women. Cancer Epidemiol Biomarkers Prev 2014; 23:1025-36. [PMID: 24836468 DOI: 10.1158/1055-9965.epi-13-1220] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
BACKGROUND There is no recent comprehensive global analysis of lung cancer mortality in women. We describe contemporary mortality rates and trends among women globally. METHODS We used the World Health Organization's Cancer Mortality Database covering 65 populations on six continents to calculate age-standardized (1960 Segi world standard) lung cancer death rates during 2006 to 2010 and annual percent change in rates for available years from 1985 to 2011 and for the most recent five data years by population and age group (30-49 and 50-74 years). RESULTS Lung cancer mortality rates (per 100,000) among young women (30-49 years) during 2006 to 2010 ranged from 0.7 in Costa Rica to 14.8 in Hungary. Rates among young women were stable or declining in 47 of 52 populations examined. Rates among women 50 to 74 years ranged from 8.8 in Georgia and Egypt to 120.0 in Scotland. In both age groups, rates were highest in parts of Europe (Scotland, Hungary, Denmark) and North America and lowest in Africa, Asia, and Latin America. Rates in older women were increasing for more than half (36/64) of populations examined, including most countries in Southern, Eastern, and Western Europe and South America. CONCLUSIONS Although widespread reductions in lung cancer in young women provide evidence of tobacco control success, rates continue to increase among older women in many countries. IMPACT More concentrated efforts to initiate or expand tobacco control programs in these countries globally will be required to attenuate the future lung cancer burden. Cancer Epidemiol Biomarkers Prev; 23(6); 1025-36. ©2014 AACR.
Collapse
Affiliation(s)
- Lindsey A Torre
- Authors' Affiliation: American Cancer Society Intramural Research, Atlanta, Georgia
| | - Rebecca L Siegel
- Authors' Affiliation: American Cancer Society Intramural Research, Atlanta, Georgia
| | - Elizabeth M Ward
- Authors' Affiliation: American Cancer Society Intramural Research, Atlanta, Georgia
| | - Ahmedin Jemal
- Authors' Affiliation: American Cancer Society Intramural Research, Atlanta, Georgia
| |
Collapse
|
11
|
Malvezzi M, Bosetti C, Rosso T, Bertuccio P, Chatenoud L, Levi F, Romano C, Negri E, La Vecchia C. Lung cancer mortality in European men: Trends and predictions. Lung Cancer 2013; 80:138-45. [DOI: 10.1016/j.lungcan.2013.01.020] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2012] [Revised: 01/08/2013] [Accepted: 01/27/2013] [Indexed: 10/27/2022]
|
12
|
Radzikowska E, Roszkowski-Sliz K, Chabowski M, Glaz P. Influence of delays in diagnosis and treatment on survival in small cell lung cancer patients. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2013; 788:355-62. [PMID: 23835998 DOI: 10.1007/978-94-007-6627-3_48] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The purpose of this study was to evaluate the influence on survival of delays in the diagnosis and treatment in an unselected population of small cell lung (SCLC) patients. Demographic and disease data of 3,479 SCLC patients were registered in the National Tuberculosis and Lung Diseases Research Institute in Warsaw, Poland during 1995-1998. In 50 % of patients, treatment started within 78 days from the appearance of first symptom(s). The median delay was 30 days (mean 47 days) and the median referral delay to a specialist was 19 days (mean 36 days). Half of SCLC patients were diagnosed during 34 days (mean 55 days). The mean time elapse from the diagnosis to the onset of therapy was 30 days (median 6 days). The multivariate analysis revealed that male gender-HR (hazard ratio = 1.2), ECOG Performance Status of 2 (HR = 1.5) and 3 + 4 (HR = 2.4), and clinical stage III (HR = 1.3) and IV (HR = 1.9) of the disease were independent negative predictors of survival. The patients treated with surgery and combined modality treatment had a better prognosis than those treated with chemoradiotherapy (HR = 1.6), chemotherapy (HR = 2.5), symptomatically (HR = 4.0), or those who refused therapy (HR = 3.9). The delay in the diagnosis and treatment had no effect on survival. Interestingly, patients who were diagnosed faster (below 42 days) actually had a worse prognosis than those diagnosed later. We conclude that a prolonged workup of SCLC patients and an extended time for treatment onset have a positive influence on survival, which may likely have to do with the determination of disease stage and more targeted treatment.
Collapse
Affiliation(s)
- E Radzikowska
- Third Department of Lung Diseases, National Institute of Tuberculosis and Lung Diseases, 26 Plocka St, 01-138, Warsaw, Poland,
| | | | | | | |
Collapse
|
13
|
Nie YL, Liu KX, Mao XY, Li YL, Li J, Zhang MM. Effect of injection of brucea javanica oil emulsion plus chemoradiotherapy for lung cancer: a review of clinical evidence. J Evid Based Med 2012; 5:216-25. [PMID: 23557502 DOI: 10.1111/jebm.12001] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
OBJECTIVE Injection of brucea javanica oil emulsion (IBJOE), one of Chinese patent drugs has been widely used for lung cancer (LC) in China, and is known to provide some favorable outcomes, in particular when it combined with conventional treatment. However, little available best evidence is known about its effect and safety. This paper aims to evaluate the effectiveness and safety of IBJOE plus chemoradiotherapy to alleviate symptoms of LC patients. METHODS A complete literature searching was conducted in databases including Chinese Biomedical Literature Database, China Academic Journals Full-text Database, Chinese Scientific Journals Database, the Cochrane Central Register of Controlled Trials, MEDLINE, and EMBASE to identify randomized controlled trials (RCTs) of IBJOE with chemoradiotherapy versus chemoradiotherapy alone for LC patients regardless of blinding, duration of treatment or duration of follow-up. All searching dates were from the beginning to December 2011. Quality of the included studies was assessed using the method by Cochrane Reviewer Handbook, and data analysis was performed using RevMan 5.10 software developed by The Cochrane Collaboration. RESULTS The searching yielded over 1371 relevant citations, most of which did not meet the inclusion criteria. Finally, only 21 RCTs involving 1619 patients were included, and all the studies were of poor quality. Pooled analyses were performed to reveal that compared with chemoradiotherapy alone, IBJOE plus chemoradiotherapy had a better complete response rate (relative risk (RR) = 1.42; 95% CI 1.05 to 1.92; P = 0.02) and improved quality of life (RR = 1.83; 95% CI 1.63 to 2.07; P < 0.00001) measured by Karnofsky Performance Status scale. In addition, there was a significant difference on the outcome of long-term survival rate, level of immune function, and some incidences of adverse effects. CONCLUSIONS IBJOE plus chemoradiotherapy may have positive effects on LC patients in response rate, improvement of quality of life, and reducing incidences of some adverse effects compared with chemoradiotherapy alone. However, the results need to be viewed with caution because of low quality of the included studies.
Collapse
Affiliation(s)
- Yan-li Nie
- Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, 610041, China
| | | | | | | | | | | |
Collapse
|
14
|
Trends in the lung cancer incidence and mortality in the Slovak and Czech Republics in the contexts of an international comparison. Clin Transl Oncol 2012; 14:659-66. [PMID: 22855145 DOI: 10.1007/s12094-012-0850-y] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2011] [Accepted: 11/21/2011] [Indexed: 10/28/2022]
Abstract
INTRODUCTION Lung cancer represents the most frequent cause of cancer-related deaths in the industrialized countries. The aim of this study was to analyze the lung cancer incidence and mortality and the possible reasons for any differences discovered in two neighboring Central European countries-the Slovak Republic. METHODS We used linear regression model when analyzing incidence and mortality; the trends are presented with corresponding 95% confidence intervals (CI) and p-value with null hypothesis being constant with time. RESULTS Statistically significant increase of age-standardized incidence (0.707/100,000/year, 95% CI 0.107-1.307, p = 0,025) and mortality (1.339/100,000/year, 95% CI 1.050-1.629, p < 0.0001) of the lung cancer was revealed in males in the Slovak Republic (1980-1991). On the contrary, values of both indicators were stabilized in the Czech Republic. Since year 1991-2005 a statistically highly significant decrease of both incidence and mortality values was observed in males, which was greater in the Slovak Republic. Peak of the curve was not reached in women population, while incidence and mortality values have significantly continuous growth in both countries. CONCLUSIONS According to the lung cancer incidence and mortality trends in both countries (in correlation with smoking prevalence) we consider the support of efforts to change the attitude towards smoking predominantly in women and younger generation to be the most accurate action to reduce these trends.
Collapse
|
15
|
Bosetti C, Bertuccio P, Negri E, La Vecchia C, Zeegers MP, Boffetta P. Pancreatic cancer: overview of descriptive epidemiology. Mol Carcinog 2012; 51:3-13. [PMID: 22162227 DOI: 10.1002/mc.20785] [Citation(s) in RCA: 133] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Pancreatic cancer mortality rates have been increasing in high-income countries between the 1950s and the 1980s, and have leveled off or declined thereafter, particularly in men. To provide a global overview of recent pancreatic cancer mortality, we analyzed official death of the world certification data derived from the World Health Organization for 35 European countries and 19 other countries over the period 1980-2007. In 2007, the highest mortality rates from pancreatic cancer were in the Baltic countries, and some central/eastern and northern European countries (over 9.5/100 000 men and 6/100 000 women), whereas the lowest ones were in Latin America and Hong Kong (below 5/100 000 men and 3/100 000 women). Japan, the USA, Russia and the European Union (EU), as well as the largest countries in the EU, had rates around 7-9/100 000 men and 5-6/100 000 women. In the early 2000s, rates have been approximately stable in many European countries, as in the USA, Japan, and Australia. In Nordic countries and the UK, where declines in rates have been observed between the 1980s and the 1990s, mortality from pancreatic cancer has tended to rise over most recent calendar years. Some persisting rises were still found in men from a few countries of southern and central/eastern Europe (with low rates in the past), as well as in the EU overall, and in women from European and Asian countries. Recent trends were generally more favorable in young adults (30-49 yr), suggesting that overall trends are likely to improve in the near future.
Collapse
Affiliation(s)
- Cristina Bosetti
- Dipartimento di Epidemiologia, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
| | | | | | | | | | | |
Collapse
|
16
|
Lin H, Zhong W, Yang X, Yan H, Wu Y. [Forecasting model of risk of cancer in lung cancer pedigree in a case-control study]. ZHONGGUO FEI AI ZA ZHI = CHINESE JOURNAL OF LUNG CANCER 2011; 14:581-7. [PMID: 21762627 PMCID: PMC6000278 DOI: 10.3779/j.issn.1009-3419.2011.07.04] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
背景与目的 对人群每年进行低剂量胸部CT筛查可提高早期肺癌诊断率,但其假阳性率较高,常导致不必要的手术。本研究拟建立肺癌家系风险度预测模型,从中细分高危人群,从而提高筛选效能。 方法 以经病理确诊的肺癌患者的家系作为研究人群,同时收集先证者的配偶家系作为对照家系,共收集先证者家系633例和对照家系565例。应用SPSS 17.0进行统计学分析。 结果 先证者家系一级亲属患肿瘤的风险性为对照组家系一级亲属的1.71倍(OR=1.71, P < 0.001)。家系中患癌个数分别为=1和≥2的两组与对照组比较有统计学差异(P=0.005,
P=0.002)。建立回归模型后赋值得到与普通人群相比的肺癌风险度为0.38-63.08(倍)。风险度为普通人群10倍以上的群体,应用本模型的正确率为88.1%。 结论 如果一级亲属患癌个数越多,患肺癌的风险越高。根据本研究建立的风险度预测模型,风险度达普通人群10倍以上的主要为重度吸烟的吸烟人群,应加强筛查。特点为:有肺部既往疾病史的重度吸烟人群,加上男性、职业暴露和一级亲属肿瘤家族史三项中的任一项;有肺部既往疾病史或重度吸烟的人群中,有职业暴露的男性且一级亲属有不少于两位肿瘤患者。
Collapse
Affiliation(s)
- Huan Lin
- Guangdong General Hospital, Guangdong Academy of Medical Sciences,
Guangzhou 510080, China
| | | | | | | | | |
Collapse
|
17
|
TP53 mutations in nonsmall cell lung cancer. J Biomed Biotechnol 2011; 2011:583929. [PMID: 21331359 PMCID: PMC3035360 DOI: 10.1155/2011/583929] [Citation(s) in RCA: 221] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2010] [Revised: 11/28/2010] [Accepted: 12/20/2010] [Indexed: 11/17/2022] Open
Abstract
The tumor suppressor gene TP53 is frequently mutated in human cancers. Abnormality of the TP53 gene is one of the most significant events in lung cancers and plays an important role in the tumorigenesis of lung epithelial cells. Human lung cancers are classified into two major types, small cell lung cancer (SCLC) and nonsmall cell lung cancer (NSCLC). The latter accounts for approximately 80% of all primary lung cancers, and the incidence of NSCLC is increasing yearly. Most clinical studies suggest that NSCLC with TP53 alterations carries a worse prognosis and may be relatively more resistant to chemotherapy and radiation. A deep understanding of the role of TP53 in lung carcinogenesis may lead to a more reasonably targeted clinical approach, which should be exploited to enhance the survival rates of patients with lung cancer. This paper will focus on the role of TP53 in the molecular pathogenesis, epidemiology, and therapeutic strategies of TP53 mutation in NSCLC.
Collapse
|
18
|
李 芳, 黄 瓅, 胡 成, 顾 其, 祝 小. [Comparative analysis of clinical epidemiology and pathological characteristics of 908 patients with primary lung cancer of Hunan Province in 1997 and 2007]. ZHONGGUO FEI AI ZA ZHI = CHINESE JOURNAL OF LUNG CANCER 2010; 13:326-30. [PMID: 20677559 PMCID: PMC6000424 DOI: 10.3779/j.issn.1009-3419.2010.04.11] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Subscribe] [Scholar Register] [Received: 11/24/2009] [Revised: 12/11/2009] [Indexed: 11/05/2022]
Abstract
BACKGROUND AND OBJECTIVE Epidemiology of lung cancer will be changed along with time and region. The aim of this study is to acknowledge the tendency of primary lung cancer in hunan province in recent years by comparing and analyzing the distribution of gender, age, area, smoking and pathology of patients who were initial diagnosed lung cancer and ancestral or permanent residence of hunan province in 1997 and 2007. METHODS Clinical data of 908 patients with primary lung cancer hospitalized in Xiangya hospital were collected and evaluated. RESULTS Compared patients in 2007 with those in 1997, ratio between male and female dropped from 3.8:1 to 2.98:1, while the proportion of young patients who were under 40 years old raised from 4.4% to 8.6% (chi2 = 4.465, P = 0.035), patients living in the county raised from 19.9% to 40.1% (chi2 = 30.670, P < 0.001), smoking rate of patients from county raised from 16.9% to 39.9% (chi2 = 24.939, P < 0.01). In addition, the proportion of rare histological types of lung cancer were also increased from 1.3% to 4.5% (chi2 = 5.142, P = 0.023). CONCLUSION Female patients, young patients, rural patients and rare histological types of lung cancer may have a tendency of increase in hunan province in recent years, whereas smoking cessation education should be strengthened.
Collapse
Affiliation(s)
- 芳 李
- />410007 长沙,中南大学湘雅医院呼吸科Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha 410007, China
| | - 瓅 黄
- />410007 长沙,中南大学湘雅医院呼吸科Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha 410007, China
| | - 成平 胡
- />410007 长沙,中南大学湘雅医院呼吸科Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha 410007, China
| | - 其华 顾
- />410007 长沙,中南大学湘雅医院呼吸科Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha 410007, China
| | - 小霞 祝
- />410007 长沙,中南大学湘雅医院呼吸科Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha 410007, China
| |
Collapse
|
19
|
Guan P, Huang D, He M, Zhou B. Lung cancer gene expression database analysis incorporating prior knowledge with support vector machine-based classification method. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH : CR 2009; 28:103. [PMID: 19615083 PMCID: PMC2719616 DOI: 10.1186/1756-9966-28-103] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/03/2009] [Accepted: 07/18/2009] [Indexed: 01/13/2023]
Abstract
Background A reliable and precise classification is essential for successful diagnosis and treatment of cancer. Gene expression microarrays have provided the high-throughput platform to discover genomic biomarkers for cancer diagnosis and prognosis. Rational use of the available bioinformation can not only effectively remove or suppress noise in gene chips, but also avoid one-sided results of separate experiment. However, only some studies have been aware of the importance of prior information in cancer classification. Methods Together with the application of support vector machine as the discriminant approach, we proposed one modified method that incorporated prior knowledge into cancer classification based on gene expression data to improve accuracy. A public well-known dataset, Malignant pleural mesothelioma and lung adenocarcinoma gene expression database, was used in this study. Prior knowledge is viewed here as a means of directing the classifier using known lung adenocarcinoma related genes. The procedures were performed by software R 2.80. Results The modified method performed better after incorporating prior knowledge. Accuracy of the modified method improved from 98.86% to 100% in training set and from 98.51% to 99.06% in test set. The standard deviations of the modified method decreased from 0.26% to 0 in training set and from 3.04% to 2.10% in test set. Conclusion The method that incorporates prior knowledge into discriminant analysis could effectively improve the capacity and reduce the impact of noise. This idea may have good future not only in practice but also in methodology.
Collapse
Affiliation(s)
- Peng Guan
- Department of Epidemiology, School of Public Health, China Medical University, Shenyang 110001, PR China.
| | | | | | | |
Collapse
|
20
|
Konac E, Dogan I, Onen HI, Yurdakul AS, Ozturk C, Varol A, Ekmecki A. Genetic variations in the hypoxia-inducible factor-1alpha gene and lung cancer. Exp Biol Med (Maywood) 2009; 234:1109-16. [PMID: 19546348 DOI: 10.3181/0902-rm-49] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Hypoxia-inducible factor-1 (HIF-1), an important genetic component of angiogenesis, becomes stable as a response to tumor hypoxia and facilitates tumor survival. The polymorphisms of the HIF-1alphagene may cause changes in the activity of this protein, which serves as a transcription factor for many genes in tumorigenesis. In this study, we have investigated the relationship between seven HIF-1alphapolymorphisms [C > T substitution in intron 8 (rs10873142), T418I (rs41508050) in exon 10, P564P (rs41492849), L580L (rs34005929), P582S (rs11549465), A588T (rs11549467) in exon 12 and dinucleotide GT repeats in intron 13 (rs10645014)] among lung cancer patients in the Turkish population. Genomic DNA was isolated from 141 lung cancer cases and 156 controls and subjected to PCR for amplification. Genotyping was carried out with RFLP and DNA sequencing methods. There was no significant difference between the lung cancer cases and controls in terms of the distribution of genotyping frequencies of seven HIF-1alphapolymorphisms (P > 0.05). No significant relationship was found between the C > T substitution in intron 8 and P582S haplotypes and development of lung cancer. In addition, there were no significant associations between the genotypes and clinopathological characteristics of the cases examined. These findings show that polymorphisms in the HIF-1alphagene do not confer susceptibility to lung cancer.
Collapse
Affiliation(s)
- Ece Konac
- Department of Medical Biology and Genetics, Faculty of Medicine, Gazi University, Besevler, 06500 Ankara, Turkey.
| | | | | | | | | | | | | |
Collapse
|
21
|
The International Epidemiology of Lung Cancer: geographical distribution and secular trends. J Thorac Oncol 2008; 3:819-31. [PMID: 18670299 DOI: 10.1097/jto.0b013e31818020eb] [Citation(s) in RCA: 539] [Impact Index Per Article: 33.7] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
This review presents the latest available international data for lung cancer incidence, mortality and survival, emphasizing the established causal relationship between smoking and lung cancer. In 2002, it was estimated that 1.35 million people throughout the world were diagnosed with lung cancer, and 1.18 million died of lung cancer-more than for any other type of cancer. There are some key differences in the epidemiology of lung cancer between more developed and less developed countries. In more developed countries, incidence and mortality rates are generally declining among males and are starting to plateau for females, reflecting previous trends in smoking prevalence. In contrast, there are some populations in less developed countries where increasing lung cancer rates are predicted to continue, due to endemic use of tobacco. A higher proportion of lung cancer cases are attributable to nonsmoking causes within less developed countries, particularly among women. Worldwide, the majority of lung cancer patients are diagnosed after the disease has progressed to a more advanced stage. Despite advances in chemotherapy, prognosis for lung cancer patients remains poor, with 5-year relative survival less than 14% among males and less than 18% among females in most countries. Given the increasing incidence of lung cancer in less developed countries and the current lack of effective treatment for advanced lung cancers, these results highlight the need for ongoing global tobacco reform to reduce the international burden of lung cancer.
Collapse
|
22
|
Abstract
INTRODUCTION Lung cancer represents the most common malignant tumour among men, and appears more and more frequently among women in many countries worldwide. The aims of this descriptive epidemiological study were to evaluate the mortality trends of all malignant tumours and lung cancer in Central Serbia from 1990 to 1999, and to estimate the incidence, mortality and the basic demographic characteristics of lung cancer in Central Serbia in 1999. MATERIAL AND METHODS The source of data concerning cancer cases in 1999 was the Cancer Registry of Central Serbia, while data of the Republic Statistics Institute were used for the analysis of mortality trends for the period 1990-1999. All rates were standardized by the direct method, to the world standard population. Confidence intervals for mortality rates were assessed with 95% level of probability. Linear regression coefficient was determined by Fisher's test. RESULTS The mortality rates showed rising tendencies for both lung cancer (y = -1876.26 + 0.96x, p = 0.028 for men; y = -654.78 + 0.33x, p = 0.001 for women) and all malignant tumours (y = -4139.88 + 2.15x, p = 0.163 for men; y = -3649.68 + 1.88x, p = 0.016 for women), with statistically significant increase being observed for all trends, except all malignant tumours among men. In the year 1999, lung cancer ranked first among men and third among women, with 29.2% and 10.3% of cancer mortality respectively. The age-specific mortality rates were much higher in men in all age groups. Mortality increased with age and the highest rates were found in the age group 70-74 for both sexes. The highest incidence and mortality rates were reported in Belgrade, Moravicki and Sumadijski district.
Collapse
|
23
|
Huang D, Guan P, Shi H, He Q, Zhou B. Reliability and accuracy of interview data in non-smoking female lung cancer case-control study. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH : CR 2008; 27:43. [PMID: 18811977 PMCID: PMC2565656 DOI: 10.1186/1756-9966-27-43] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 06/10/2008] [Accepted: 09/24/2008] [Indexed: 02/06/2023]
Abstract
Background Valid interview data is critical to the final results of the study. The purpose of this study was to investigate the reliability of epidemiological data obtained in non-smoking female lung cancer case-control study in China. Methods Fifty-six pairs of cases and controls, 10% percent of all the collected subjects were re-interviewed by three interviewers who underwent identical standardized training. A limited number of questions included in the original survey were asked again, the responses from the re-interview were compared with the original interview. Kappa was calculated by negative rates of agreement, positive rates of agreement and total rates of agreement to the accordance degree between the two interviews. Results The Kappa values were all more than 0.5 in all the studied indexes. The Kappa values descended from 0.92 in family history of cancer to 0.56 in oral contraception use. Errors in collecting and classifying data did occur, and were especially common for complicated clinical events, such as a drug exposure occurring many years before. Conclusion We identified four sources of this variability, three in collecting the data, and one in coding. As a result of these findings, strategies are proposed for improving the quality of interview data obtained in epidemiological research. Before finding a good solution, the strategy of data collecting and coding should be simple and easy to inspect.
Collapse
Affiliation(s)
- Desheng Huang
- Department of Epidemiology, School of Public Health, China Medical University, Shenyang 110001, PR China.
| | | | | | | | | |
Collapse
|
24
|
Van der Heyden JHA, Schaap MM, Kunst AE, Esnaola S, Borrell C, Cox B, Leinsalu M, Stirbu I, Kalediene R, Deboosere P, Mackenbach JP, Van Oyen H. Socioeconomic inequalities in lung cancer mortality in 16 European populations. Lung Cancer 2008; 63:322-30. [PMID: 18656277 DOI: 10.1016/j.lungcan.2008.06.006] [Citation(s) in RCA: 73] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2008] [Revised: 06/02/2008] [Accepted: 06/07/2008] [Indexed: 10/21/2022]
Abstract
OBJECTIVES This paper aims to describe socioeconomic inequalities in lung cancer mortality in Europe and to get further insight into socioeconomic inequalities in lung cancer mortality in different European populations by relating these to socioeconomic inequalities in overall mortality and smoking within the same or reference populations. Particular attention is paid to inequalities in Eastern European and Baltic countries. METHODS Data were obtained from mortality registers, population censuses and health interview surveys in 16 European populations. Educational inequalities in lung cancer and total mortality were assessed by direct standardization and calculation of two indices of inequality: the Relative Index of Inequality (RII) and the Slope Index of Inequality (SII). SIIs were used to calculate the contribution of inequalities in lung cancer mortality to inequalities in total mortality. Indices of inequality in lung cancer mortality in the age group 40-59 years were compared with indices of inequalities in smoking taking into account a time lag of 20 years. RESULTS The pattern of inequalities in Eastern European and Baltic countries is more or less similar as the one observed in the Northern countries. Among men educational inequalities are largest in the Eastern European and Baltic countries. Among women they are largest in Northern European countries. Whereas among Southern European women lung cancer mortality rates are still higher among the high educated, we observe a negative association between smoking and education among young female adults. The contribution of lung cancer mortality inequalities to total mortality inequalities is in most male populations more than 10%. Important smoking inequalities are observed among young adults in all populations. In Sweden, Hungary and the Czech Republic smoking inequalities among young adult women are larger than lung cancer mortality inequalities among women aged 20 years older. CONCLUSIONS Important socioeconomic inequalities exist in lung cancer mortality in Europe. They are consistent with the geographical spread of the smoking epidemic. In the next decades socioeconomic inequalities in lung cancer mortality are likely to persist and even increase among women. In Southern European countries we may expect a reversal from a positive to a negative association between socioeconomic status and lung cancer mortality. Continuous efforts are necessary to tackle socioeconomic inequalities in lung cancer mortality in all European countries.
Collapse
|
25
|
Raimondi S, Maisonneuve P, Löhr JM, Lowenfels AB. Early onset pancreatic cancer: evidence of a major role for smoking and genetic factors. Cancer Epidemiol Biomarkers Prev 2007; 16:1894-7. [PMID: 17855711 DOI: 10.1158/1055-9965.epi-07-0341] [Citation(s) in RCA: 88] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Pancreatic cancer ranks 4th as a cause of cancer mortality and in approximately 5% to 10% of patients, this lethal tumor develops before age 50. We used age-, sex-, and country-specific cancer incidence and mortality data to describe the burden of early onset pancreatic cancer (EOPC) worldwide. We also reviewed the current published evidence on smoking and genetic factors associated with EOPC. We found an excess of EOPC resulting in a substantial number of years-of-life-lost in countries from Central and Eastern Europe. Worldwide, the proportion of EOPC is strongly correlated with lung cancer mortality (R(2) = 0.53), suggesting that approximately half of the variation in the proportion of EOPC could be explained by smoking. The unusual pattern of the incidence of pancreatic cancer by gender and race supports the primary role of smoking in the etiology of EOPC: the excess male-to-female rate ratio, attributable mainly to smoking, gradually approaches unity with increasing age. Moreover, male-to-female rate ratios are greater in blacks than in whites only in younger patients. Published studies also identified genetic alterations involved either alone or in association with smoking in the development of EOPC. In conclusion, EOPC constitutes only 1% to 5% of the total deaths from pancreatic cancer worldwide, but is responsible for 20% to 30% of the total number of years-of-life-lost caused by the disease. Smoking and genetic mutations are the major identified risk factors and seem to be even more important for EOPC than for PC in older age groups.
Collapse
Affiliation(s)
- Sara Raimondi
- Division of Epidemiology and Biostatistics, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
| | | | | | | |
Collapse
|
26
|
Page RM, Ihasz F, Simonek J, Klarova R, Hantiu I. Cigarette smoking, friendship factors, and social norm perceptions among central and Eastern European high school students. JOURNAL OF DRUG EDUCATION 2006; 36:213-31. [PMID: 17345915 DOI: 10.2190/p00l-2061-461x-336q] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
Abstract
Studies investigating smoking behavior among adolescents living in post-communistic Central-European countries are sparse. This study focused on the relationship between cigarette smoking, certain friendship factors, and social norm perceptions among 1,886 Central-Eastern European adolescents from high schools in Hungary, Slovakia, Czech Republic, and Romania. Smoking behavior was related to having friends who smoke, ease or difficulty making new friends, time spent with friends after school and during evenings, and estimations of the prevalence of smoking by schoolmates. Because these youth appear to overestimate the prevalence of smoking by schoolmates, the use of a norms-correction strategy may have potential merit in smoking prevention efforts targeting these adolescents. Smoking prevention and reduction are critical issues for Central-Eastern European youth because they appear to smoke cigarettes at a high rate.
Collapse
Affiliation(s)
- Randy M Page
- Department of Health Science, Brigham Yong University, Provo, UT 84602, USA.
| | | | | | | | | |
Collapse
|
27
|
Bosetti C, Levi F, Lucchini F, Negri E, La Vecchia C. Lung cancer mortality in European women: recent trends and perspectives. Ann Oncol 2005; 16:1597-604. [PMID: 16014639 DOI: 10.1093/annonc/mdi313] [Citation(s) in RCA: 63] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Lung cancer mortality in men has been declining since the late 1980s in most European countries. In women, although rates are still appreciably lower than those for men, steady upward trends have been observed in most countries. To quantify the current and future lung cancer epidemic in European women, trends in lung cancer mortality in women over the last four decades were analyzed, with specific focus on the young. PATIENTS AND METHODS Age-standardized (world standard) lung cancer mortality rates per 100,000 women-at all ages, and truncated 35--64 and 20--44 years-were derived from the WHO for the European Union (EU) as a whole and for 33 separate European countries. Joinpoint regression analysis was used to identify points where a significant change in trends occurred. RESULTS In the EU overall, female lung cancer mortality rates rose by 23.8% between 1980--1981 and 1990--1991 (from 7.8 to 9.6/100,000), and by 16.1% thereafter, to reach the value of 11.2/100,000 in 2000--2001. Increases were smaller in the last decade in several countries. Only in England and Wales, Latvia, Lithuania, Russia and Ukraine did female lung cancer mortality show a decrease over the last decade. In several European countries, a decline in lung cancer mortality in young women (20--44 years) was observed over the last decade. CONCLUSIONS Although female lung cancer mortality is still increasing in most European countries, the more favorable trends in young women over recent calendar years suggest that if effective interventions to control tobacco smoking in women are implemented, the lung cancer epidemic in European women will not reach the levels observed in the USA.
Collapse
Affiliation(s)
- C Bosetti
- Istituto di Ricerche Farmacologiche 'Mario Negri', Milan, Italy.
| | | | | | | | | |
Collapse
|
28
|
Primic-Zakelj M, Zadnik V, Zagar T. Is cancer epidemiology different in Western Europe to that in Eastern Europe? Ann Oncol 2005; 16 Suppl 2:ii27-9. [PMID: 15958471 DOI: 10.1093/annonc/mdi725] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Affiliation(s)
- M Primic-Zakelj
- Institute of Oncology Ljubljana, Epidemiology and Cancer Registries, Ljubljana, Slovenia
| | | | | |
Collapse
|
29
|
Pauk N, Kubík A, Zatloukal P, Krepela E. Lung cancer in women. Lung Cancer 2005; 48:1-9. [PMID: 15777966 DOI: 10.1016/j.lungcan.2004.10.009] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2004] [Revised: 10/18/2004] [Accepted: 10/19/2004] [Indexed: 01/10/2023]
Abstract
Lung cancer is one of the most important avoidable causes of death around the world, it is the most widespread carcinoma with a very poor prognosis, and is the leading cause of cancer death in both developed and developing countries. At present more men than women die each year from lung cancer, but in recent years a rapid increase in lung cancer mortality has been observed among women in developed countries, contrasting with a levelling off or decrease among men. The rising trend in female lung cancer mortality has been observed to parallel with the past and current prevalence of cigarette smoking among women in the United States and elsewhere. An important role of other factors acting either as independent risk factors or interacting with the effect of smoking has been suggested by some studies among women, among them genetic, biologic and hormonal factors, and probably some factors related to the environment and lifestyle. There is a controversy concerning the claim that women have a different susceptibility to tobacco carcinogens, which might or might not be greater than men do. Since tobacco is far and away the strongest epidemiological risk factor for the development of lung cancer, comprehensive smoking control efforts are the priority in the prevention of lung cancer among women.
Collapse
Affiliation(s)
- Norbert Pauk
- Department of Pneumology and Thoracic Surgery, Charles University, 3rd Faculty of Medicine, University Hospital Na Bulovce, and Postgraduate Medical Institute, Budínova 2, 18081 Prague, Czech Republic.
| | | | | | | |
Collapse
|
30
|
Chen S, Yu L, Jiang C, Zhao Y, Sun D, Li S, Liao G, Chen Y, Fu Q, Tao Q, Ye D, Hu P, Khawli LA, Taylor CR, Epstein AL, Ju DW. Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J Clin Oncol 2005; 23:1538-47. [PMID: 15735129 DOI: 10.1200/jco.2005.06.108] [Citation(s) in RCA: 77] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
PURPOSE Tumor necrosis treatment (TNT) uses degenerating tumor cells and necrotic regions of tumors as targets for radioimmunotherapy. Previous studies in animal tumor models and clinical trials have demonstrated that when linked to the therapeutic radionuclide iodine-131, recombinant chimeric TNT antibody ((131)I-chTNT) can deliver therapeutic doses to tumors regardless of the location or type of malignancy. Therapeutic efficacy and toxicity of (131)I-chTNT in advanced lung cancer patients were studied in this pivotal registration trial. PATIENTS AND METHODS Patients with advanced lung cancer were treated with systemic or intratumoral injection of (131)I-chTNT in eight oncology centers in China. The objective response rate (ORR) was assessed as the primary end point. RESULTS All 107 patients who were entered onto the study and completed therapy had experienced treatment failure after prior radiotherapy or chemotherapy a mean of three times. The results showed an ORR of 34.6% (complete response, 3.7%; partial response, 30.8%; no change, 55.1%; and progressive disease, 10.3%) in all patients and 33% in 97 non-small-cell lung cancer patients. A biodistribution study demonstrated excellent localization of the radioactivity in tumors in both systemically and intratumorally injected patients. The most obvious adverse side effect was mild and reversible bone marrow suppression. CONCLUSION Radioimmunotherapy with (131)I-chTNT was well tolerated and can be used systemically or locally to treat refractory tumors of the lung.
Collapse
Affiliation(s)
- Shaoliang Chen
- Zhongshan Hospital and Tumor Hospital, Fudan University, Shanghai, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Levi F, Lucchini F, Negri E, La Vecchia C. Trends in mortality from major cancers in the European Union, including acceding countries, in 2004. Cancer 2004; 101:2843-50. [PMID: 15526321 DOI: 10.1002/cncr.20666] [Citation(s) in RCA: 81] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
BACKGROUND In May 2004, 10 additional countries joined the European Union (EU), including a total of 75 million inhabitants. Most of these were from central and eastern European countries with comparably high cancer mortality rates and with relatively unfavorable trends. Therefore, it is important to provide updated mortality data regarding major cancers in various countries and to analyze trends for the current population of the EU. METHODS The authors considered mortality rates (directly standardized to the world standard population) for all cancers and for 8 major cancer sites in the year 2000 in the 25 countries of the EU and analyzed corresponding trends since 1980 using data derived from the World Health Organization data base. RESULTS For men, overall cancer mortality in the year 2000 varied by a factor > 2 between the highest rate of 258.5 per 100,000 men in Hungary and the lowest rate of 122.0 per 100,000 men in Sweden. Central and Eastern European accession countries had the highest rates not only for lung and other tobacco-related cancers but also for gastrointestinal cancers and leukemias. The geographic pattern was different and the range of variation was smaller for women, i.e., between 136.7 per 100,000 women in Denmark and 76.4 per 100,000 women in Spain in the year 2000. In the EU as a whole, lung cancer mortality in men peaked at 55.4 per 100,000 men in 1988 and declined thereafter to 46.7 per 100,000 men in 2000. Gastric cancer steadily declined from 19.7 per 100,000 men in 1980 to 10.1 per 100,000 men in 2000. Other major sites showed moderately favorable trends over the last few years. In women, breast cancer peaked at 21.7 per 100,000 in 1989 and declined to 18.9 per 100,000 in 2000. Mortality from gastric, (cervix) uterus, and intestinal cancers demonstrated steady decreases, but lung cancer increased from 7.7 per 100,000 women in 1980 to 11.1 per 100,000 women in 2000. The increase in lung cancer mortality in women age < 55 years was 38% between 1990 and 2000 (from 2.16 per 100,000 women to 2.99 per 100,000 women), reflecting the spread of tobacco smoking among women in the EU over the last few decades. CONCLUSIONS The priority for further reduction of cancer mortality in the EU remains tobacco control together with more widespread availability of modern diagnostic and treatment procedures for neoplasms that are amenable to treatment.
Collapse
Affiliation(s)
- Fabio Levi
- Cancer Epidemiology Unit and Cancer Registries of Vaud and Neuchâtel, Institut Universitaire de Médecine Sociale et Préventive, Lausanne, Switzerland.
| | | | | | | |
Collapse
|